1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Gan & Lee Pharmaceuticals.
  6. News
  7. Summary
    603087   CNE100003ZH1

GAN & LEE PHARMACEUTICALS.

(603087)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Gan & Lee Pharmaceuticals Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021

04/29/2021 | 12:44pm EDT

Gan & Lee Pharmaceuticals Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 548.603 million compared to CNY 469.915 million a year ago. Operating income was CNY 238.089 million compared to CNY 153.593 million a year ago. Net income was CNY 190.077 million compared to CNY 123.111 million a year ago. Basic earnings per share from continuing operations was CNY 0.34 compared to CNY 0.34 a year ago.


ę S&P Capital IQ 2021
All news about GAN & LEE PHARMACEUTICALS.
04/27Gan & Lee Pharmaceuticals. Reports Earnings Results for the First Quarter Ended March 3..
CI
03/10Gan & Lee Pharmaceuticals Begins First-In-Human Trial in U.S. for Investigational Drug,..
AQ
03/10Gan & Lee Pharmaceuticals. Begins First-In-Human Trial in U.S. for Investigational Drug..
CI
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces U.S. FDA Clearance of Investigational New..
CI
2021China’s Drug Procurement Program Cuts Insulin Costs by Around 48%
MT
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Nine Months Ended September..
CI
2021GAN & LEE PHARMACEUTICALS : Concludes Phase 3 Studies of Gan & Lee Insulin Glargine (GL-GL..
AQ
2021Gan & Lee Pharmaceuticals. Reports Earnings Results for the Half Year Ended June 30, 20..
CI
2021GAN & LEE PHARMACEUTICALS : New Data on Phase 1 Proposed Biosimilar Gan & Lee Insulins Asp..
AQ
2021Gan & Lee Pharmaceuticals Co., Ltd. Announces Positive Phase 1 Clinical Trial Results a..
CI
More news
Financials
Sales 2022 4 002 M 594 M 594 M
Net income 2022 1 533 M 228 M 228 M
Net Debt 2022 - - -
P/E ratio 2022 15,6x
Yield 2022 -
Capitalization 23 860 M 3 541 M 3 541 M
Capi. / Sales 2022 5,96x
Capi. / Sales 2023 4,92x
Nbr of Employees 3 278
Free-Float 20,5%
Chart GAN & LEE PHARMACEUTICALS.
Duration : Period :
Gan & Lee Pharmaceuticals. Technical Analysis Chart | 603087 | CNE100003ZH1 | MarketScreener
Technical analysis trends GAN & LEE PHARMACEUTICALS.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 42,49
Average target price
Spread / Average Target -
EPS Revisions
Managers and Directors
Zhong Ru Gan Chairman
Yan Sun Independent Director
Yan Qing He Independent Director
Guo Jun Zheng Independent Director
Kai Du Director & Director-International Department
Sector and Competitors
1st jan.Capi. (M$)
GAN & LEE PHARMACEUTICALS.-39.59%3 556
CSL LIMITED-4.63%92 449
SAMSUNG BIOLOGICS CO.,LTD.-15.17%42 728
BIOGEN INC.-17.31%29 053
WUXI BIOLOGICS (CAYMAN) INC.-42.68%28 509
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD.-25.12%22 801